新冠病毒mRNA疫苗第四剂在奥密克戎BA.2和BA.5流行期间对老年人群的有效性：韩国的一项全国性队列研究（K-COVE）
Effectiveness of A Fourth Dose of COVID-19 mRNA Vaccine in the Elderly Population During the Omicron BA.2 and BA.5 Circulation: A Nationwide Cohort Study in Korea (K-COVE).
作者信息
Park Seon Kyeong, Choe Young June, Jang Eun Jung, Kim Ryu Kyung, Lim Do-Sang, Yi Seonju, Lee Sangwon, Kwon Geun-Yong, Shin Jee Yeon, Choi Sang-Yoon, Jeong Mi Jin, Park Young-Joon
机构信息
Korea Disease Control and Prevention Agency, Cheongju, South Korea.
Korea University, and Anam Hospital, Seoul, South Korea.
出版信息
Open Forum Infect Dis. 2023 Mar 1;10(3):ofad109. doi: 10.1093/ofid/ofad109. eCollection 2023 Mar.
We estimate the effectiveness of a fourth dose booster of coronavirus disease 2019 mRNA vaccine in individuals aged ≥60 years during Omicron BA.2 and BA.5 circulation in Korea. The effectiveness against critical infection was 67.7% (95% confidence interval, 50.7%-78.8%) at 31-60 days and 62.1% (95% confidence interval, 45.5%-73.7%) at 61-90 days.
我们评估了2019冠状病毒病mRNA疫苗第四剂加强针在韩国奥密克戎BA.2和BA.5毒株传播期间对60岁及以上人群的有效性。对重症感染的有效性在接种后31至60天为67.7%（95%置信区间，50.7%-78.8%），在61至90天为62.1%（95%置信区间，45.5%-73.7%）。
Zotero 插件